MedTrace Logo

ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers

NCT01185626 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2017-05-09

No results posted yet for this study

Summary

Earlier diagnoses and improved treatments have contributed to the growing cohort of cancer survivors. Nevertheless, these patients remain at risk for adverse long-term or late physical or psychosocial effects of cancer and its treatment. There is increasing recognition to improve information disclosure and cancer survivorship care. The American Institute of Medicine (IOM) and Health Council of the Netherlands both recommend that cancer survivors receive a summary of their course of treatment as a formal document, that also includes recommendations for subsequent cancer surveillance, management of late effects, and strategies for health promotion, the Survivorship Care Plan (SCP). However, no evidence exists concerning the positive and negative effects of the implementation of the SCP in daily clinical practice. The purpose of this study is to assess the impact of SCP care in routine clinical practice on cancer survivors' satisfaction with information disclosure and care, quality of life, illness perception, and health care use.

Conditions

Interventions

OTHER

SCP care

Sponsors & Collaborators

  • Comprehensive Cancer Centre The Netherlands

    collaborator OTHER

  • Dutch Cancer Society

    collaborator OTHER

  • Lonneke van de Poll-Franse

    lead OTHER

Principal Investigators

  • Lonneke V van de Poll-Franse, Dr. Prof. · Tilburg University, The Netherlands

  • Nicole PM Ezendam, Dr. · The Netherlands Comprehensive Cancer Organisation

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185626 on ClinicalTrials.gov